BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...

Catherine Diefenbach, MD, an American Society of Hematology expert and director of the Clinical Lymphoma Program at NYU Langone's Perlmutter Cancer Center, discussed the evolving state of diffuse ...

The phase 3 STARGLO study met its primary endpoint of improved overall survival, according to Columvi’s manufacturer, Genetech. Treatment with the bispecific antibody Columvi (glofitamab-gxbm) in ...

Sellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...

Matthew S. McKinney, MD, reflects on his first experience of treating a patient with diffuse large B-cell lymphoma (DLBCL) as a new attending at Duke University. The patient, a woman with multiple ...

NEW YORK, June 27, 2024 /PRNewswire/ -- The global diffuse large B-cell lymphoma (DLBCL) therapeutics market size is estimated to grow by USD 2.24 billion from 2024-2028, according to Technavio. The ...

What we expect to see for aggressive lymphoma at the American Society of Hematology meeting in December is probably ...

The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary efficacy and safety of epcoritamab in patients with non-Hodgkin’s lymphoma (NHL), ...

Anna Sureda, MD, PhD, of the Catalan Institute of Oncology, discusses the evolving treatment landscape for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or follicular ...

A combo of the novel bispecific antibody mosunetuzumab and the antibody-drug conjugate polatuzumab vedotin (Mosun-Pola) significantly outperformed standard chemotherapy in transplant-ineligible ...